GRAP2

Across TCGA pan-cancer cohorts, GRAP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GRAP2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GRAP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GRAP2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where GRAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.832	0.425	.003	34	view →
PDAC	DFS	Quartile	All	0.946	0.698	.002	24	view →
LUAD	DFS	Tertile	All	0.876	0.477	<.001	17	view →
GBM	OS	Median	All	0.332	0.717	<.001	16	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	6	view →
LSCC	DFS	Tertile	II,III,IV	0.482	0.811	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GRAP2–CCRCC (DFS)

Open the CCRCC breakdown →